[Federal Register Volume 86, Number 48 (Monday, March 15, 2021)]
[Notices]
[Page 14331]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-05272]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Engineered 
Tumor Infiltrating Lymphocytes for Cancer Therapy; Correction

AGENCY: National Institutes of Health, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services, National 
Institutes of Health published a Notice in the Federal Register on 
February 25, 2021. That Notice requires a correction in the 
SUPPLEMENTARY INFORMATION section.

SUPPLEMENTARY INFORMATION:

Correction

    In the Federal Register of February 25, 2021, in FR Doc. 2021-
03873, on page 11548, as found within the Supplementary Information 
section, correct to read:

    The use of the Licensed Patent Rights to develop, manufacture, 
distribute, sell, and use autologous tumor infiltrating lymphocyte 
(TIL) adoptive cell therapy products for the treatment of metastatic 
melanoma, lung, breast, bladder, and HPV-positive cancers. 
Specifically excluded from this Agreement are cell therapy products 
involving TIL genetically modified for reactivity against cancer-
specific mutations or TIL selected for reactivity against cancer-
specific mutations, unless such cell therapy products are a 
combination of unselected, unmodified TIL therapy with the 
Licensee's proprietary technologies or the Licensee's in-licensed 
technologies.

    The field of use described in the Notice was found to be incorrect. 
The correction addresses this discrepancy by accurately stating the 
field of use which the NIH intends to grant to Iovance Biotherapeutics, 
Inc for the disclosed federally owned invention.
ADDRESSES: Requests for copies of the patent applications, inquiries, 
and comments relating to the contemplated Exclusive Patent License 
should be directed to: Andrew Burke, Ph.D., Senior Technology Transfer 
Manager, NCI Technology Transfer Center, Telephone: (240)-276-5484; 
Email: [email protected].

    Dated: March 9, 2021.
Daniel R Hernandez,
Federal Register Officer, National Institutes of Health.
[FR Doc. 2021-05272 Filed 3-12-21; 8:45 am]
BILLING CODE 4140-01-P